Surgical Site Infections Therapeutics Market Size in the 7MM is expected to increase by 2034, estimates DelveInsight

Posted on
by

Surgical Site Infections Therapeutics Market Size in the 7MM is expected to increase by 2034, estimates DelveInsight

DelveInsight’s “Surgical Site Infections Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Surgical Site Infections, historical and forecasted epidemiology as well as the Surgical Site Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Discover Key Insights into the Surgical Site Infections Market with DelveInsight’s In-Depth Report @ Surgical Site Infections Market Size

 

Key Takeaways from the Surgical Site Infections Market Report

  • The Surgical Site Infections market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • According to findings, surgical site infection occur in 2% to 4% of all patients undergoing inpatient surgical procedures.
  • Findings show that the overall incidence of surgical site infections was approximately 10% in the early 2000s, decreased to 7% by 2007, and further declined to 5% by 2020.
  • The leading Surgical Site Infections Companies such as MinaPharm Pharmaceuticals, Duke Clinical Research Institute, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., GlaxoSmithKline, Durata Therapeutics, Cubist Pharmaceutical, Zurex Pharma, Inc., and others
  • Promising Surgical Site Infections Therapies such as Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard, and others

 

Navigate the complexities of the Surgical Site Infections Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Surgical Site Infections Market Forecast. Click here to get more insights @ Surgical Site Infections Treatment Market

 

Surgical Site Infections Epidemiology Segmentation in the 7MM

  • Total Prevalence of Surgical Site Infections
  • Prevalent Cases of Surgical Site Infections by severity
  • Gender-specific Prevalence of Surgical Site Infections
  • Diagnosed Cases of Episodic and Chronic Surgical Site Infections

 

Download the report to understand which factors are driving Surgical Site Infections epidemiology trends @ Surgical Site Infections Prevalence

 

Surgical Site Infections Emerging Drugs

 

  • D-PLEX100: PolyPid

D-PLEX is a new formulation of extended release of Doxycycline. D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable. The company is conducting a Phase III, prospective, multinational, multicenter, randomized, controlled, two-arm, double blind study to assess efficacy and safety of D-PLEX administered concomitantly with the Standard of Care (SoC), compared to a SoC treated control arm, in prevention of post abdominal surgery incisional infection.

 

  • XF-73 Nasal gel: Destiny Pharma

XF-73 Nasal gel, a dicationic porphyrin derivative, possesses strong bactericidal properties through a unique mechanism of action. It is a newly developed compound aimed at preventing Staphylococcal infections following surgical procedures. XF-73 Nasal gel is fast acting, requires very few applications and it has a very low propensity to develop bacterial resistance. Thus, XF-73 Nasal gel, preventing post-surgical infections, has the potential to reduce hospitalization stay, accelerate recovery and rehabilitation and improve quality of life for patients undergoing vital surgeries. In April 2024, Destiny Pharma disclosed audited results for 2023, announcing a strategic review to advance XF-73 nasal through Phase III trials. They also re-evaluated trial costs, developing a cost-effective design, and enhanced market understanding for partnerships.

 

Surgical Site Infection Market Outlook

The market for surgical site infection treatments is anticipated to grow significantly, driven by key players like PolyPid and Destiny Pharma, who are advancing their lead candidates through various clinical stages. PolyPid’s D-PLEX100 and Destiny Pharma’s XF-73, among other innovative therapies, aim to provide targeted and effective solutions for preventing and treating surgical site infection. The rising prevalence of surgical site infection, the increasing number of surgical procedures, and enhanced diagnostic technologies underscore the urgent need for advanced treatments.

 

Get In-Depth Knowledge on Surgical Site Infections Market Trends and Forecasts with DelveInsight @ Surgical Site Infections Treatment Market

 

Surgical Site Infections Therapies and Companies

  • Ciprodiazole: MinaPharm Pharmaceuticals
  • DFA-02 Antibiotic Gel: Duke Clinical Research Institute
  • ZuraPrep: Zurex Pharma, Inc.
  • Ertapenem: Merck Sharp & Dohme LLC
  • XF-73: Destiny Pharma Plc
  • D-PLEX: PolyPid Ltd.
  • cefuroxime: GlaxoSmithKline
  • Dalbavancin: Durata Therapeutics
  • daptomycin: Cubist Pharmaceutical
  • ZuraGard: Zurex Pharma, Inc.

 

Surgical Site Infections Treatment Market

Treatment for surgical site infections (SSIs) typically involves antibiotics tailored to the specific pathogens identified through wound cultures. The choice of antibiotics is crucial for effectively targeting the infection and reducing resistance. In some cases, if the infection does not respond to antibiotic therapy or if it involves deeper tissues or foreign materials, additional surgical intervention may be required to remove infected tissue, drain abscesses, or address complications. Prompt and appropriate management is essential to prevent the spread of infection, reduce recovery time, and minimize the risk of long-term complications.

 

Gain a strategic edge in the Surgical Site Infections Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Surgical Site Infections Market Forecast. Click here to lead in advancements @ Surgical Site Infections Clinical Trials Assessment

 

Scope of the Surgical Site Infections Market Report

  • Study Period: 2020-2034
  • Coverage: 7MM
  • Surgical Site Infections Companies: MinaPharm Pharmaceuticals, Duke Clinical Research Institute, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., GlaxoSmithKline, Durata Therapeutics, Cubist Pharmaceutical, Zurex Pharma, Inc., and others
  • Surgical Site Infections Therapies: Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard, and others
  • Surgical Site Infections Therapeutic Assessment: Surgical Site Infections current marketed and Surgical Site Infections emerging therapies
  • Surgical Site Infections Market Dynamics: Surgical Site Infections market drivers and Surgical Site Infections market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Surgical Site Infections Unmet Needs, KOL’s views, Analyst’s views, Surgical Site Infections Market Access and Reimbursement

 

Table of Contents

1. Surgical Site Infections Market Report Introduction

2. Executive Summary for Surgical Site Infections

3. SWOT analysis of Surgical Site Infections

4. Surgical Site Infections Patient Share (%) Overview at a Glance

5. Surgical Site Infections Market Overview at a Glance

6. Surgical Site Infections Disease Background and Overview

7. Surgical Site Infections Epidemiology and Patient Population

8. Country-Specific Patient Population of Surgical Site Infections

9. Surgical Site Infections Current Treatment and Medical Practices

10. Surgical Site Infections Unmet Needs

11. Surgical Site Infections Emerging Therapies

12. Surgical Site Infections Market Outlook

13. Country-Wise Surgical Site Infections Market Analysis (2020-2034)

14. Surgical Site Infections Market Access and Reimbursement of Therapies

15. Surgical Site Infections Market Drivers

16. Surgical Site Infections Market Barriers

17. Surgical Site Infections Appendix

18. Surgical Site Infections Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage